Puma Biotechnology, Inc. Stock

$3.52

0.71% today

Nasdaq, Jul 08, 07:16 pm CET

ISIN

US74587V1070

Symbol

PBYI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Puma Biotechnology, Inc. Stock price

$3.54

-7.27 67.25% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.04 1.12%

ISIN

US74587V1070

Symbol

PBYI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$175.7m

Enterprise Value

$138.5m

Net debt

positive

Cash

$93.2m

Shares outstanding

49.6m

Valuation (TTM | estimate)

P/E

4.6 | 7.3

P/S

0.8 | 0.8

EV/Sales

0.6 | 0.6

EV/FCF

4.4

P/B

1.8

Financial Health

Equity Ratio

43.2%

Return on Equity

32.9%

ROCE

34.0%

ROIC

47.1%

Debt/Equity

0.6

Financials (TTM | estimate)

Revenue

$232.7m | $222.2m

EBITDA

$48.7m | $34.7m

EBIT

$37.2m | $25.8m

Net Income

$38.1m | $24.0m

Free Cash Flow

$31.2m

Growth (TTM | estimate)

Revenue

2.7% | -3.6%

EBITDA

29.7% | -18.4%

EBIT

43.4% | -16.6%

Net Income

147.5% | -20.9%

Free Cash Flow

-12.2%

EPS

$0.8

FCF per Share

$0.6

Short interest

6.3%

Employees

172

Rev per Employee

$1.3m

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Get Started for Free Today

Puma Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Puma Biotechnology, Inc. forecast:

3x Hold

38%

4x Sell

50%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Puma Biotechnology, Inc. forecast:

Buy

13%

Hold

38%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Puma Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	233 233	3% 3% 100%
- Direct Costs	64 64	7% 7% 28%
Gross Profit	168 168	1% 1% 72%
- Selling and Administrative Expenses	76 76	14% 14% 33%
- Research and Development Expense	55 55	8% 8% 24%
EBITDA	49 49	30% 30% 21%
- Depreciation and Amortization	11 11	1% 1% 5%
EBIT (Operating Income) EBIT	37 37	43% 43% 16%
Net Profit	38 38	148% 148% 16%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Puma Biotechnology, Inc. Stock News

Neutral

Business Wire

●

6 days ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq Listing Rule 5635(c)(4).

Positive

Seeking Alpha

●

13 days ago

Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now.

Neutral

Business Wire

●

about one month ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement I...

More Puma Biotechnology, Inc. News

Company Profile

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Head office	United States
CEO	Alan Auerbach
Employees	172
Founded	2010
Website	www.pumabiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now